The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The use of a transient transfected expression system to deliver high quality bispecific T-cell engager drug product, NVG-111, to the clinic for a fraction of the cost and time associated with the development and use of a producer cell line.
 
Kieran O'Donovan
Employment - NovalGen
Stock and Other Ownership Interests - NovalGen
Travel, Accommodations, Expenses - NovalGen
 
Shivam Bhatt
Employment - NovalGen
Stock and Other Ownership Interests - NovalGen
 
Annalisa Baccaro
Employment - Novalgen
Stock and Other Ownership Interests - NovalGen
Research Funding - Novalgen
Travel, Accommodations, Expenses - Novalgen
 
Dinusha Fernando
No Relationships to Disclose
 
Angel Smith
Employment - NovalGen
Stock and Other Ownership Interests - NovalGen
Research Funding - NovalGen (Inst)
Travel, Accommodations, Expenses - NovalGen
 
Ephraim Gbajumo
No Relationships to Disclose
 
Tomasz Bobrzynski
Employment - NovalGen
 
Jenny McIntosh
Stock and Other Ownership Interests - Freeline Therapeutics
Consulting or Advisory Role - Freeline Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties from BioMarin
 
Jasmine Gore
No Relationships to Disclose
 
Amit C. Nathwani
Employment - Freeline Therapeutics; NovalGen
Leadership - Freeline Therapeutics; NovalGen
Stock and Other Ownership Interests - Freeline Therapeutics; NovalGen
Research Funding - Biomarin
Patents, Royalties, Other Intellectual Property - Revenue share agreement with St Jude for LP1-FIX licence Revenue share agreement with UCL for FVIII licence and technology licenced to Freeline and Novalgen
 
Kerry Chester
Employment - NovalGen
Stock and Other Ownership Interests - NovalGen
Consulting or Advisory Role - NovalGen
Patents, Royalties, Other Intellectual Property - I am an inventor on antibody patents filed by UCL Business Ltd, The Network Building, 97 Tottenham Court Road, London W1T 4TP, UK
Expert Testimony - Allen & Overy LLP
 
David Granger
Employment - NovalGen
Stock and Other Ownership Interests - Crescendo Biologics; GlaxoSmithKline; NovalGen
Research Funding - NovalGen
Travel, Accommodations, Expenses - NovalGen